Ingenuity Systems and Geospiza partner to enable seamless next-generation sequencing analysis workflow

Ingenuity® Systems, a leading provider of information solutions for life science researchers, and Geospiza, Inc., the market leading developer of laboratory management and genetic analysis software, today announced a collaboration to enable a seamless next-generation sequencing analysis workflow.  The companies will integrate their software products, GeneSifter® and IPA®, to enable researchers to obtain deep biological insights from their project samples through a rapid and reliable workflow to analyze and visualize next-generation sequencing data.

"This is a perfect synthesis of expertise, in my opinion," says Christopher Mason, Ph.D., Professor of Computational Genomics at the Institute for Computational Biomedicine at Weill Cornell Medical College (WCMC), and a member of the Tri-Institutional Program on Computational Biology and Medicine of WCMC, Rockefeller, and Memorial Sloan-Kettering Cancer Center.  "Geospiza has already worked with every modality of sequencing from every known platform, and will work with all of the emerging technologies.  They have shown that they can easily convert raw data to per-base dynamics, and the logical next step for contextualizing genetic, epigenetic, transcriptional, and/or proteomic common and rare variation is to overlay these changes within the known and predicted pathways and drug targets that are well-annotated and curated by Ingenuity.  I can't wait to use their merged tools and databases."

"The promise of NGS is dependent on a researcher's ability to quickly and accurately distill millions of reads and hundreds of datasets down to a manageable list of the most interesting and relevant genes," stated Todd Smith, CTO, Geospiza.  "Our integration with IPA will accelerate drug discovery and 'omics research pipelines by enabling NGS researchers to understand and visualize their data in the context of known biological processes, functions, diseases, pathways and relationships, through IPA's powerful analysis capabilities and the timely, detailed information in the Ingenuity® Knowledge Base."

"Our main objective is to help our joint customers confidently answer their research questions in a relevant biological context," stated Doug Bassett, Ph.D., CSO and CTO, Ingenuity Systems. "It is important to provide a streamlined way for researchers to move from a list of genes, isoforms, or variants all the way to identifying drug targets, validating biomarkers, generating hypotheses, and understanding drug mechanism of action.  IPA supports multiple data types, disease areas, and experimental platforms, and the GeneSifter and IPA integration continues to strengthen this focus by offering a complete and reliable platform for the analysis and interpretation of NGS data."